Jennifer Gjerde
Publications
Academic articles
2025
The bisphenol microplastics issue in marine bivalves
Veterinarska stanica
56
p. 13-27
2022
Shotgun proteomics approaches for authentication, biological analyses, and allergen detection in feed and food-grade insect species
Food Control
137
p. 1-11
2020
Validation and Determination of 25(OH) Vitamin D and 3-Epi25(OH)D3 in Breastmilk and Maternal- and Infant Plasma during Breastfeeding
Nutrients
12
2019
Prognostic impact of genetic variants of CYP19A1 and UGT2B17 in a randomized trial for endocrine-responsive postmenopausal breast cancer
The Pharmacogenomics Journal
p. 1-8
2019
Drug monitoring of tamoxifen metabolites predicts vaginal dryness and verifies a low discontinuation rate from the Norwegian Prescription Database
Breast Cancer Research and Treatment
177
p. 185-195
2019
Prognostic impact of genetic variants of CYP19A1 and UGT2B17 in a randomized trial for endocrine-responsive postmenopausal breast cancer
The Pharmacogenomics Journal 2019
2018
Effect of Whey and Herring Roe Protein administered as a supplement to young healthy adults – A pilot study. I: Blue Growth: Aquaculture, Fisheries, Market and Health Perspectives..
Orkana Forlag 2018
2018
A prospective, longitudinal, breast cancer biobank (PBCB) in western Norway.
Europe Biobank Week (EBW)
2016
A pooled analysis of CYP2D6 genotype in breast cancer prevention trials of low-dose tamoxifen
Breast Cancer Research and Treatment
159
p. 97-108
2016
A pooled analysis of CYP2D6 genotype in breast cancer prevention trials of low-dose tamoxifen
Breast Cancer Res Treat
159(1):97-108.
2015
The active tamoxifen metabolite endoxifen (4OHNDtam) strongly down-regulates cytokeratin 6 (CK6) in MCF-7 breast cancer cells
PLOS ONE
10
2015
Estrogens correlate with PELP1 expression in ER positive breast cancer
PLOS ONE
10:e0134351
2015
Estrogens Correlate with PELP1 Expression in ER Positive Breast Cancer
PLoS One
10(8)
2015
The active tamoxifen metabolite endoxifen (4OHNDtam) strongly down-regulates cytokeratin 6 (CK6) in MCF-7 breast cancer cells
PLoS One
10(4)
2014
Phospholipids from herring roe improve plasma lipids and glucose tolerance in healthy, young adults
Lipids in Health and Disease
13:82
2014
Illness uncertainty in breast cancer patients: Validation of the 5-item short form of the Mishel Uncertainty in Illness Scale
European Journal of Oncology Nursing
p. 1-7
2014
Phospholipids from herring roe improve plasma lipids and glucose tolerance in healthy, young adults
Lipids Health Dis.
May 17
2013
Serum concentrations of tamoxifen and its metabolites increase with age during steady-state treatment
Breast Cancer Research and Treatment
141
p. 243-248
2013
Changes in adipose glucocorticoid metabolism before and after bariatric surgery assessed by direct hormone measurements
Obesity
21
p. 2495-2503
2013
A randomized phase II presurgical trial of weekly low-dose tamoxifen versus raloxifene versus placebo in premenopausal women with estrogen receptor-positive breast cancer
Breast Cancer Research
15
2013
Serum concentrations of tamoxifen and its metabolites increase with age during steady-state treatment.
Breast Cancer Res Treat
2013
Changes in adipose glucocorticoid metabolism before and after bariatric surgery assessed by direct hormone measurements
Obesity (Silver Spring)
2013
A randomized phase II pre-surgical trial of weekly low-dose tamoxifen versus raloxifene versus placebo in premenopausal women with estrogen receptor positive breast cancer
Breast Cancer Res
15(3)
2013
Breaking away: high fracture rates may merit a new trial of adjuvant endocrine therapy in Scandinavian breast cancer patients
Acta Oncol.
52(4)
p. 861-862
2012
The nuclear receptors NUR77, NURR1 and NOR1 in obesity and during fat loss
International Journal of Obesity
36
p. 1195-1202
2012
Steroid receptor coactivators, HER-2 and HER-3 expression is stimulated by tamoxifen treatment in DMBA-induced breast cancer
BMC Cancer
12
2012
Tissue distribution of 4-hydroxy-N-desmethyltamoxifen and tamoxifen-N-oxide
Breast Cancer Research and Treatment
134
p. 693-700
2012
Steroid receptor coactivators, HER-2 and HER-3 expression is stimulated by tamoxifen treatment in DMBA-induced breast cancer.
BMC Cancer
12:247
2011
Efficacy of tamoxifen based on cytochrome P450 2D6, CYP2C19 and SULT1A1 genotype in the Italian Tamoxifen Prevention Trial
The Pharmacogenomics Journal
11
p. 100-107
2011
Functional polymorphisms in UDP-glucuronosyltransferases and recurrence in tamoxifen-treated breast cancer survivors
Cancer Epidemiology, Biomarkers and Prevention
20
p. 1937-1943
2011
Sulfotransferase 1A1 and estrogen receptor influence the 17β-estradiol level in tumor tissues of postmenopausal women
Cancer Epidemiol Biomarkers Prev.
20(9)
2011
Efficacy of tamoxifen based on cytochrome P450 2D6, CYP2C19 and SULT1A1 genotype in the Italian Tamoxifen Prevention Trial.
Pharmacogenomics J.
11(2)
p. 100-7
2011
The nuclear receptors NUR77, NURR1 and NOR1 in obesity and during fat loss.
Int J Obes (Lond)
2010
Associations between tamoxifen, estrogens, and FSH serum levels during steady state tamoxifen treatment of postmenopausal women with breast cancer
BMC Cancer
10
2010
Effect of low-dose tamoxifen on steroid receptor coactivator 3/amplified in breast cancer 1 in normal and malignant human breast tissue
Clinical Cancer Research
16
p. 2176-2186
2010
Associations between tamoxifen, estrogens, and FSH serum levels during steady state tamoxifen treatment of postmenopausal women with breast cancer.
BMC Cancer
2010
Effect of low-dose tamoxifen on steroid receptor coactivator 3/amplified in breast cancer 1 in normal and malignant human breast tissue.
Clin Cancer Res. 2010
16(7)
p. 2176-86.
2010
Efficacy of tamoxifen based on cytochrome P450 2D6, CYP2C19 and SULT1A1 genotype in the Italian Tamoxifen Prevention Trial.
Pharmacogenomics J.
2008
Tamoxifen impairs both longitudinal and cortical bone growth in young male rats
Journal of Bone and Mineral Research
23
p. 1267-1277
2008
Effects of CYP2D6 and SULT1A1 genotypes including SULT1A1 gene copy number on tamoxifen metabolism
Annals of Oncology
19
p. 56-61
2008
Tamoxifen Impairs Both Longitudinal and Cortical Bone Growth in Young Male Rats.
J Bone Miner Res.
2007
Randomized dose-ranging trial of tamoxifen at low doses in hormone replacement therapy users
Journal of Clinical Oncology
25
p. 4201-4209
2007
A study of association between estrogen and tamoxifen metabolism, cytochrome 2D6 and sulfotransferae 1A1 polymorphisms, and sulfotransferase 1A1 gene copy number during steady sate tamoxifen treatment
Breast Cancer Research and Treatment
106
p. S144-S144
2007
Randomized dose-ranging trial of tamoxifen at low doses in hormone replacement therapy users.
J Clin Oncol.
25(27)
2007
A study of associations between estrogen and tamoxifen metabolism, cytochrome 2D6 and sulfotransferase 1A1 polymorphisms, and sulfotransferase 1A1 gene copy number during steady state tamoxifen treatment.
Breast Cancer Res Treat.
106
2007
Effect of CYP2D6 and SULT1A1 Genotypes on the serum concentration of 4-OHtamoxifen and 4-OH-N-Demethyltamoxifen during steady state treatment of breast cancer patients.
Breast
16
2006
Pretreatment with tamoxifen does not change acute epirubicin cardiotoxicity in rats
98
p. 231-234
2006
Pretreatment with tamoxifen does not change acute epirubicin cardiotoxicity in rats.
Basic Clin Pharmacol Toxicol.
98(2).
p. 231-4
2005
Induction of hepatic drug-metabolising enzymes and tamoxifen metabolite profile in relation to administration route during low-dose treatment in nude rats
Journal of Steroid Biochemistry and Molecular Biology
94
p. 489-498
2005
Identification and quantification of tamoxifen and four metabolites in serum by liquid chromatography-tandem mass spectrometry
Journal of Chromatography A
1082
p. 6-14
2005
Relationship between CYP2D6 and SULT1A1 genotypes and serum concentrations of tamoxifen and its metabolites during steady state treatment in breast cancer patients.
Breast Cancer Res Treat.
94
2005
Identification and quantification of tamoxifen and four metabolites in serum by liquid chromatography-tandem mass spectrometry.
J Chromatogr A.
1082(1)
p. 6-14.
2005
Induction of hepatic drug-metabolising enzymes and tamoxifen metabolite profile in relation to administration route during low-dose treatment in nude rats.
J Steroid Biochem Mol Biol.
94(5)
p. 489-98.
2004
Tamoxifen and metabolite concentrations in serum and breast cancer tissue during three dose regimens in randomized preoperative trial
Clinical Cancer Research
10
p. 2336-2343
2004
Tamoxifen and metabolite concentrations in serum and breast cancer tissue during three dose regimens in a randomized preoperative trial.
Clin Cancer Res.
10(7)
p. 2336-43.
2003
Tamoxifen administration and metabolism in nude mice and nude rats
Journal of Steroid Biochemistry and Molecular Biology
84
p. 361-367
2003
Tamoxifen administration and metabolism in nude mice and nude rats.
J Steroid Biochem Mol Biol.
84(2-3)
p. 361-7.
Other journal contributions
2013
Breaking away: High fracture rates may merit a new trial of adjuvant endocrine therapy in Scandinavian breast cancer patients
Acta Oncologica
52
p. 861-U216
2013
Associations between tamoxifen and age during steady state tamoxifen treatment of postmenopausal women with breast cancer
121
2010
Effects of CYP2C19 genotype on tamoxifen and estrogen metabolism
European Journal of Cancer
8
p. 60-60
2008
A study of associations between estrogen and tamoxifen metabolism, cytochrome 2D6 and sulfotransferase 1A1 polymorphisms, and sulfotransferase 1A1 gene copy number during steady state tamoxifen treatment
Breast Cancer Research and Treatment
109
p. 592-592
2007
Effect of CYP2D6 and SULT1A1 genotypes on the serum concentration of 4-hydroxytamoxifen and 4-hydroxy-N-demethyltamoxifen during steady state treatment of breast cancer patients
Breast
16
p. S15-S15
2007
A study of associations between estrogen and tamoxifen metabolism, cytochrome 2D6 and sulfotransferase 1A1 polymorphisms, and sulfotransferase 1A1 gene copy number during steady state tamoxifen treatment
Breast Cancer Research and Treatment
S106
2005
Relationship between CYP2D6 and SULT1A1 genotypes and serum concentrations of tamoxifen and its metabolites during steady state treatment in breast cancer patients
Breast Cancer Research and Treatment
94
p. S236-S237
Scientific lectures
2010
Estrogen Receptor degradation
2005
Distribution of tamoxifen in serum and breast cancer tissue and its effects on sex hormone-binding globulin (SHBG)
Poster
2024
Microplastic analysis in marine sediments utilizing quantum cascade laser -IR spectroscopy and pyrolysis gas chromatography mass spectrometry
2021
Developing av LCMS method for determination of Buthylated hydroxyanisole, Buthylated hydroxytoluene and degradation products
Feed 2021 Conference
2018
A prospective, longitudinal, breast cancer biobank (PBCB) in western Norway
2011
The nuclear receptors NURR77, NURR1 and NOR1 in obesity and during fat loss
2010
The influence of tamoxifen treatment on the expression levels of liver receptor homolog (LHR-1)
2010
Effects of CYP2C19 genotype on tamoxifen and estrogen metabolism
2010
Distribution of tamoxifen and five metabolites into normal and malignant human breast cancer tissue during conventional and low dose treatment
2010
Expression of Steroid Receptor Coactivators and HER-2/neu in normal and malignant breast tissue in controls and tamoxifen treated patients
2009
Relations between FSH, SHBG and tamoxifen metabolism during steady state tamoxifen treatment
2007
A study of association between estrogen and tamoxifen metabolism, cytochrome 2D6 and sulfotransferae 1A1 polymorphisms, and sulfotransferase 1A1 gene copy number during steady sate tamoxifen treatment
2007
Effect of CYP2D6 and SULT1A1 Genotypes on the serum concentration of 4-OHtamoxifen and 4-OH-N-Demethyltamoxifen during steady state treatment of breast cancer patients
2005
Relationship between CYP2D6 and SULT1A1 genotype and serum concentration of tamoxifen and its metabolites during steady state treatment in breast cancer patients
2005
Relationship between CYP2D6 and SULT1A1 genotypes and serum concentrations of tamoxifen and its metabolites during steady state treatment in breast cancer patients
2005
Effects of low-dose tamoxifen treatment on expression of drug-metabolising enzymes in rat liver in relation to administration route
2004
Quantification of serum tamoxifen and metabolites by liquid chromatography-tandem mass spectrometry
2004
Tamoxifen metabolism and induction of hepatic drug-metabolizing enzymes in nude rats
2002
Tamoxifen metabolism in immunocompromised rats and mice
Reports and dissertations
2010
CYP2C19 single nucleotide polymorphisms And their effects on the metabolism of Tamoxifen in breast cancer patients
2008
Tamoxifen treatment of breast cancer: Pharmacogenetics and therapeutic drug monitoring
Is this your profile? Edit your profile (login)